首页> 外文OA文献 >Design, development and optimisation of veterinary intravaginal controlled release drug delivery systems
【2h】

Design, development and optimisation of veterinary intravaginal controlled release drug delivery systems

机译:兽医阴道内控释给药系统的设计,开发和优化

摘要

This Thesis begins by discussing the application of controlled drug delivery to the intravaginal delivery of hormones to control the oestrous cycle of farmed animals, with particular emphasis on the delivery of progestagens to cattle and sheep. The introduction highlights the recent advances made by animal physiologists in their knowledge of the oestrous cycle in cattle and sheep and how these advances have impacted upon the manner in which currently available intravaginal controlled release products are used. In addition it discusses the advances pharmaceutical scientists have made in response to the new knowledge.The CIDR®1900 Cattle insert is a commercially available silicone based intravaginal delivery system containing the natural steroid progesterone for fertility regulation in cattle. It was designed in 1987 to be inserted for 12 days. Advances made in oestrous cycle understanding by animal scientists have resulted in this product being inserted for much shorter treatment periods of 7 days. Rathbone et al. recently optimised the CIDR®1900 Cattle insert for seven day insertion periods. The outcome of these scientists work was a manufactured prototype which, when compared to the CIDR®1900 Cattle insert, contained a reduced initial drug load and a much lower residual drug load after use. For commercial production the prototype insert needed to be scaled up. This process required detailed pharmaceutical characterisation, invitro release assessment, invivo bioequivalency and chemical and physical stability studies to be performed on the scaled up product (CIDR®1380 Cattle insert) to ensure the success of the scale up process. This characterisation process forms Chapters Two and Three of this Thesis.Knowledge of the mechanism of release of a drug from a pharmaceutical product provides the formulation scientist with the necessary insight to optimise, further develop or recognise the potential and limitations of a product. Chapter Four explores the mechanism of release of progesterone from the silicone based CIDR® Cattle insert both invitro and invivo. Cumulative release data from both invitro and invivo studies were fitted against conventional mathematical models to determine the mechanism of release of progesterone from the CIDR® Cattle insert. In addition, an experimental method was developed to assess the validity of the models. The method involved taking thin consecutive horizontal slices from the surface of CIDR® Cattle inserts after various periods of release. Cumulative release of progesterone, both invitro and invivo, was linear when plotted against the square root of time, suggesting that release from the CIDR® Cattle insert occurred in accordance with the square root of time mechanism. However, experimental evidence from the horizontal slicing technique only supported the curve fitting evidence for invitro release. When the insert was investigated invivo, the slicing method indicated that a novel release mechanism was in operation which was better described by a zero order process.Chapters Five and Six of this Thesis direct their focus to oestrus control in sheep. Chapter Five utilises information gained from both Rathbone et al. and the work performed in this Thesis on the CIDR® Cattle insert to characterise and optimise the commercially available sheep equivalent of the CIDR ® 1900 Cattle insert (known as the CIDR® Sheep and Goat insert). The Chapter successfully characterises the CIDR® Sheep and Goat insert, defines the parameters of, and tests, an optimised version of this sheep product.The final Chapter of this Thesis investigates the use of poly-(ε-caprolactone) as a platform for the intravaginal delivery of progesterone to control oestrus in sheep. Silicone has certain limitations as a drug delivery platform, and with animal physiologists recent advances in knowledge, pharmaceutical scientists will need more versatile delivery platforms to develop intravaginal drug delivery systems which fulfil the future demands of the animal scientists.
机译:本论文首先讨论了控制药物输送到荷尔蒙的阴道内输送中的应用,以控制饲养动物的雌性周期,尤其着重于孕激素向牛和羊的输送。引言着重介绍了动物生理学家在了解牛和羊的发情周期方面的最新进展,以及这些进展如何影响当前使用的阴道内控释产品的使用方式。此外,它还讨论了药物科学家响应新知识而取得的进步。CIDR®1900牛插入物是一种可商购的基于硅胶的阴道内给药系统,其中含有天然甾体黄体酮,可调节牛的生育力。它于1987年设计,可插入12天。动物科学家对发情周期的理解取得了进展,导致该产品的插入时间缩短了7天。 Rathbone等。最近对CIDR®1900牛插入物进行了优化,可插入7天。这些科学家工作的结果是制造出了原型,与1900牛插入物相比,使用后的初始药物载量减少,残留药物载量大大降低。对于商业生产,原型插件需要扩大规模。此过程要求对放大的产品(CIDR®1380牛插入物)进行详细的药物表征,体外释放评估,体内生物等效性以及化学和物理稳定性研究,以确保放大过程的成功。这种表征过程构成了本论文的第二章和第三章。对药物从药物产品中释放的机理的了解为制剂科学家提供了必要的见识,以优化,进一步开发或认识产品的潜力和局限性。第四章探讨了孕酮从有机硅基的CIDR®Cattle插入物在体外和体内释放的机理。将来自体外和体内研究的累积释放数据与常规数学模型进行拟合,以确定黄体酮从CIDR®牛插入物中释放的机理。此外,开发了一种实验方法来评估模型的有效性。该方法涉及在不同的释放期后从CIDR®牛插入物表面获取连续的薄水平切片。当针对时间的平方根作图时,孕激素在体内和体外的累积释放都是线性的,这表明从CIDR®牛插入物中释放的时间与时间的平方根一致。但是,水平切片技术的实验证据仅支持体外释放的曲线拟合证据。当对插入物进行体内研究时,切片方法表明一种新的释放机制正在运行,可以通过零级过程更好地描述。本文的第五章和第六章将其重点放在控制绵羊发情上。第五章利用从Rathbone等人获得的信息。以及本文对CIDR®牛插入物进行的工作,以表征和优化与CIDR®1900牛插入物(被称为CIDR®绵羊和山羊插入物)的市售绵羊等效产品。本章成功地描述了CIDR®绵羊和山羊插入物的特性,定义了该绵羊产品的优化版本的参数并进行了测试。本论文的最后一章研究了聚(ε-己内酯)作为该产品的平台的用途。阴道内孕激素的输送以控制绵羊的发情。有机硅作为药物传递平台有一定的局限性,并且随着动物生理学家最近知识的发展,药物科学家将需要更通用的传递平台来开发满足动物科学家未来需求的阴道内药物传递系统。

著录项

  • 作者

    Ogle Colin Roger;

  • 作者单位
  • 年度 2014
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号